0000899243-22-002880.txt : 20220121 0000899243-22-002880.hdr.sgml : 20220121 20220121161531 ACCESSION NUMBER: 0000899243-22-002880 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220119 FILED AS OF DATE: 20220121 DATE AS OF CHANGE: 20220121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dunn Judith CENTRAL INDEX KEY: 0001811904 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38978 FILM NUMBER: 22546094 MAIL ADDRESS: STREET 1: C/O SEELOS THERAPEUTICS, INC. STREET 2: 300 PARK AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-19 0 0001680581 Fulcrum Therapeutics, Inc. FULC 0001811904 Dunn Judith C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks Stock Option (right to buy) 12.69 2022-01-19 4 A 0 140890 0.00 A 2032-01-18 Common Stock 140890 140890 D This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service. President, Research & Development /s/ Peter Thomson, as attorney-in-fact for Judith A. Dunn 2022-01-21